Evidence map›Paper›PMID 41799427›Full record

ArticleClinical, cosmetic and investigational dermatology2026

Concurrent Nasal Sebaceous Carcinoma and Right-Hand Squamous Cell Carcinoma: A Case Report and Literature Review.

Ying Yang

Abstract readCase Reports
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ying YangDepartment of Dermatology, Zigong Fourth People's Hospital, Zigong, People's Republic of China.ORCID 0009-0002-4209-7018

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer with an increasing incidence. Sebaceous carcinoma (SC) is a rare, highly aggressive malignant tumor of cutaneous appendage origin, mainly occurring in the head and neck region (most commonly in the ocular area), and extremely rare in the nasal region. A literature review showed that only 3 cases of collision tumors composed of SC and squamous cell carcinoma (SCC) have been reported previously, and there is no report of concurrent SC and cSCC in different sites of the same patient. Combined with a literature review, this paper reports an 84-year-old female patient with progressive ulcerative skin lesions on the right hand and nose for 5 years. Initial biopsy suggested cSCC of the hand and sebaceous adenoma of the nose. After surgical excision, postoperative pathology and immunohistochemistry confirmed well-differentiated cSCC of the right hand and SC of the nose. Oncology consultation recommended adjuvant radiotherapy for nasal SC after surgery, which was refused by the patient's family due to her advanced age; no recurrence or metastasis was observed in either of the two lesions during the 5-month postoperative follow-up period. By analyzing this rare case of multicentric primary cutaneous malignant tumors combined with relevant literature, we emphasize that elderly patients with long-standing chronic skin lesions require comprehensive screening to avoid missed diagnosis. Accurate diagnosis relies on pathology and immunohistochemistry, surgical resection is the main treatment, and long-term follow-up is crucial. This case enriches the clinical data on concurrent SC and cSCC, providing references for their diagnosis and treatment.

Indexed as

case reportcutaneous squamous cell carcinomasebaceous carcinomatreatment

Identifiers

PMID41799427
PMCPMC12966887

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.